Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to
Australian biotech Immutep has begun a clinical trial partnership with Germany’s Merck KGaA and Pfizer to develop a new cancer immunotherapy combination therapy.